Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition presenterar lovande prekliniska Parkinsondata vid konferensen AD/PD 2025

STOCKHOLM, SVERIGE 1 april 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar nya prekliniska data som visar att golexanolon...
April 01, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition presents recent preclinical data showing that...
March 21, 2025 03:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments årsredovisning för 2024 har publicerats

STOCKHOLM, SVERIGE 21 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att årsredovisningen för 2024 har offentliggjorts. Årsredovisningen finns nu tillgänglig på...
March 21, 2025 03:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development Annual Report 2024 published

STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024. The report is now available to download at...
March 18, 2025 10:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition lämnar uppdatering om pågående klinisk fas 1b/2a-studie

STOCKHOLM, SVERIGE 18 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition lämnat en uppdatering om den pågående kliniska fas 1b/2a-studien av...
March 18, 2025 10:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing...
March 13, 2025 04:30 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag AnaCardio får ytterligare patent i EU för läkemedelskandidaten AC01

STOCKHOLM, SVERIGE 13 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har beviljats EU-patent för läkemedelskandidaten AC01 som en inotrop...
March 13, 2025 04:30 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an...
March 12, 2025 10:23 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag PharmNovo erhåller positivt utlåtande från FDA inför planerad IND-ansökan om fas 2a-studie

STOCKHOLM, SVERIGE 12 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget PharmNovo erhöll positiv återkoppling rörande bolagets längst framskridna...
March 12, 2025 10:23 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

STOCKHOLM, SWEDEN – March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug...